Cara Therapeutics (CARA) is on an uptrend again, with recent news of the U.S. Food and Drug Administration’s (FDA) approval of the company’s KORSUVA injection. The drug is for treating moderate-to-severe pruritus, occurring in chronic kidney disease (CKD) patients. The approval comes after two phase-III trials with positive results. The company recently released its Q3-2021 report, which included a revenue surprise of $20 million, as well as insight into its go-to-market strategy for KORSUVA. The company’s stock price is up around 26% over the last six months. (See Cara Therapeutics stock charts on TipRanks) I rate the company as bullish.
https://www.tipranks.com/news/article/cara-therapeutics-bullish-on-fda-approval?utm_source=advfn.com&utm_medium=referral
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Cara Therapeutics Charts.
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Cara Therapeutics Charts.